ADARx Pharmaceuticals, Inc. — Form SCHEDULE 13D
Filed October 5, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 8/100
What the filing says
On October 5, 2026, SR One Capital Management, LLC and multiple affiliated investment funds (SR One Capital Fund I Aggregator, LP; SR One Capital Partners I, LP; SR One Capital Opportunities Fund I, LP; SR One Co-Invest III, LLC; and AMZL, LP)—all controlled by Simeon George, M.D.—executed an agreement to file a joint Schedule 13D with respect to their ownership of ADARx Pharmaceuticals, Inc. shares. The filing is purely procedural: multiple related parties agreed to file a single Schedule 13D statement rather than separate statements per SEC Rule 13d-1(k)(1). No acquisition, sale, stake percentage, share count, or dollar amount is disclosed in this excerpt.
Why this rating
Procedural 13D coordination agreement; no transaction details, prices, or ownership % disclosed. Routine administrative filing with minimal direct business impact unless underlying stake is material.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.